Skip to main content
. 2021 Nov 16;135(3):360–368. doi: 10.1016/j.amjmed.2021.10.026

Figure 2.

Figure 2

COVID-19-directed interventions in black patients prior to and after EUA approval of remdesivir. Clustered bar graph showing proportions of Black patients pre- and post-EAU of remdesivir (periods 1 and 2, respectively), in additional to the proportion of non-Black patients in period 2 receiving COVID-19 therapies. P value is derived from the comparison between Black patients and non-Black patients in their receipt of COVID-19 therapies in period 2. COVID-19 = coronavirus disease 2019; EAU = emergency use authorization.